Calla Lily Clinical Care, a women’s health-focused medical technology company, has joined Wellcome Leap’s Focused Antibiotics programme – a new $50m funded programme to transform how antibiotics are delivered and address the growing global threat of antimicrobial resistance (AMR). Founded by the Wellcome Trust in 2020, US non-profit Wellcome Leap… Read More
Nigel Brooksby, Executive Chair at AMR Bio reinforces the warnings about antimicrobial resistance (AMR) and highlights that the threat isn’t being taken seriously enough. Antimicrobial resistance has become a familiar threat that has bred complacency There is no shortage of evidence to show that antimicrobial resistance is one of the greatest long-term threats to global health. The scientific consensus continues… Read More
The Fleming Initiative has enlisted the support of Amazon Web Services (AWS) to boost the organisation’s battle against antimicrobial resistance (AMR). AWS is believed to have offered several million pounds worth of cloud and AI technology, as well as technical support, for the Initiative’s AMR intelligence platform. Read More
Biotechnology company AMR Bio has submitted written comments in efforts to shape the US National Action Plan to combat antibiotic-resistant bacteria. AMR Bio wrote to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) ahead of the council’s 27th public meeting on 16 June 2026, contributing to the next iteration… Read More
Diana Turner takes a look at drug discovery in India, a country making the shift from scale to innovation. While the Indian pharmaceuticals sector has long held a key global position… Read More
This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called ‘Why more work is needed to fight antimicrobial resistance’. In the article, DDW Editor Reece Armstrong speaks to Professor… Read More
Immunotherapy company Centauri Therapeutics has extended its Series A financing to £30 million ($40.6 million) to support its lead candidate targeting Gram-negative bacterial infections. The funding was extended thanks to a £6m ($8.1 million) investment from the AMR Action Fund. The financing from AMR Action Fund, the world’s… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research into bacterial species and diseases broke new ground. Elsewhere, vaccines could… Read More
News round-up for 17 – 21 November by Bruno Quinney, Content Team at DDW. This week in DDW, research into bacterial species and diseases gets top billing. Elsewhere, vaccines could offer groundbreaking solutions to cervical and lung cancer. The top stories: Medication detrimental to gut microbiome,… Read More
GSK and the Fleming Initiative have launched six major new research programmes aiming to combat antimicrobial resistance (AMR). The six ‘Grand Challenges’ will bring together scientific expertise and the latest technologies, including AI, to find new ways to slow the progress of AMR. The project has been backed by… Read More
DDW Editor Reece Armstrong speaks to Dr Neil Murray, CEO of Liverpool-based RenewVax, that is developing the first universal vaccine for invasive pneumococcal disease, as well as vaccines for other antimicrobial resistant bacterial infections. … Read More
PACE, one of the UK’s largest public-private initiatives targeting early-stage antimicrobial drug and diagnostic development, has launched its third round of funding to support innovative projects. The initiative has announced £6 million ($8 million) in funding for antibacterial treatment innovations, aiming to tackle resistant bacterial infections and… Read More
This is the latest episode of the free DDW narrated podcast, titled “Strategies and challenges in therapeutic development and lab practice”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The inner workings of antibiotics”, “Targeting advances in immunotherapies”, and… Read More
An investment of $1 billion to increase access to innovative antibiotics and high-quality treatment of antimicrobial resistance (AMR), could boost the European Union’s (EU) economy by $88 billion a year, by the year 2050. This is according to new research from the Center for Global Development, the… Read More
Birmingham scientists have identified essential genetic code for a method called plasmid curing, which aims to ‘displace’ antibiotic resistance genes from bacteria. Plasmids play a crucial role in allowing bacteria to share beneficial genes rapidly in a changing environment, most concerningly when they carry genes conferring resistance… Read More
Newly published Phase III trial results suggest the new antibiotic gepotidacin could treat uncomplicated urogenital gonorrhoea (GC). The trial showed that gepotidacin was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular ceftriaxone plus oral azithromycin combined therapy, a leading combination treatment… Read More
